Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.

<h4>Background and objectives</h4>Hidradenitis suppurativa (HS) significantly affects the patient`s quality of life and leads to multiple medical consultations. Aim of this study was to assess the utilization of medical care of HS patients.<h4>Patients and methods</h4>All pat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Verena Gerlinde Frings, Oliver Schöffski, Matthias Goebeler, Dagmar Presser
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d2f9359a5cba420997558482037d47eb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d2f9359a5cba420997558482037d47eb
record_format	dspace
spelling	oai:doaj.org-article:d2f9359a5cba420997558482037d47eb2021-12-02T20:18:43ZEconomic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.1932-620310.1371/journal.pone.0255560https://doaj.org/article/d2f9359a5cba420997558482037d47eb2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0255560https://doaj.org/toc/1932-6203<h4>Background and objectives</h4>Hidradenitis suppurativa (HS) significantly affects the patient`s quality of life and leads to multiple medical consultations. Aim of this study was to assess the utilization of medical care of HS patients.<h4>Patients and methods</h4>All patients presenting in 2017 for an outpatient, day patient and / or inpatient treatment with leading claim type HS at the Department of Dermatology, University Hospital Würzburg, were included. Primary outcome was the economic burden of HS patients, measured by resource utilization in €.<h4>Results</h4>The largest share of the direct medical costs for HS were the inpatient costs with a leading surgical diagnosis-related group (DRG). Antiseptics were the predominant topical prescription. While doxycycline was the most frequently prescribed systemic therapy, adalimumab was the main cost driver. The difference between in-patient (€ 110.25) and outpatient (€ 26.34) direct non-medical costs was statistically significant (p < 0.001). With regards to indirect medical costs, a statistically significantly higher loss of gross value added (inpatient mean € 1,827.00; outpatient mean € 203.00) and loss of production (inpatient mean € 1,026.00; outpatient mean € 228.00) could be noted (p < 0.001), respectively.<h4>Conclusions</h4>The present study on disease-specific costs of HS confirms that the hospital care of patients with this disease is cost-intensive. However, the primary goal of physicians is not and should not be to save costs regarding their patients`treatment, but rather the premise to utilize the existing resources as efficient as possible. Reducing the use of costly therapeutics and inpatient stays therefore requires more effective therapy options with an improved cost-benefit profile.Verena Gerlinde FringsOliver SchöffskiMatthias GoebelerDagmar PresserPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 8, p e0255560 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Verena Gerlinde Frings Oliver Schöffski Matthias Goebeler Dagmar Presser Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.
description	<h4>Background and objectives</h4>Hidradenitis suppurativa (HS) significantly affects the patient`s quality of life and leads to multiple medical consultations. Aim of this study was to assess the utilization of medical care of HS patients.<h4>Patients and methods</h4>All patients presenting in 2017 for an outpatient, day patient and / or inpatient treatment with leading claim type HS at the Department of Dermatology, University Hospital Würzburg, were included. Primary outcome was the economic burden of HS patients, measured by resource utilization in €.<h4>Results</h4>The largest share of the direct medical costs for HS were the inpatient costs with a leading surgical diagnosis-related group (DRG). Antiseptics were the predominant topical prescription. While doxycycline was the most frequently prescribed systemic therapy, adalimumab was the main cost driver. The difference between in-patient (€ 110.25) and outpatient (€ 26.34) direct non-medical costs was statistically significant (p < 0.001). With regards to indirect medical costs, a statistically significantly higher loss of gross value added (inpatient mean € 1,827.00; outpatient mean € 203.00) and loss of production (inpatient mean € 1,026.00; outpatient mean € 228.00) could be noted (p < 0.001), respectively.<h4>Conclusions</h4>The present study on disease-specific costs of HS confirms that the hospital care of patients with this disease is cost-intensive. However, the primary goal of physicians is not and should not be to save costs regarding their patients`treatment, but rather the premise to utilize the existing resources as efficient as possible. Reducing the use of costly therapeutics and inpatient stays therefore requires more effective therapy options with an improved cost-benefit profile.
format	article
author	Verena Gerlinde Frings Oliver Schöffski Matthias Goebeler Dagmar Presser
author_facet	Verena Gerlinde Frings Oliver Schöffski Matthias Goebeler Dagmar Presser
author_sort	Verena Gerlinde Frings
title	Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.
title_short	Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.
title_full	Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.
title_fullStr	Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.
title_full_unstemmed	Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.
title_sort	economic analysis of the costs associated with hidradenitis suppurativa at a german university hospital.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/d2f9359a5cba420997558482037d47eb
work_keys_str_mv	AT verenagerlindefrings economicanalysisofthecostsassociatedwithhidradenitissuppurativaatagermanuniversityhospital AT oliverschoffski economicanalysisofthecostsassociatedwithhidradenitissuppurativaatagermanuniversityhospital AT matthiasgoebeler economicanalysisofthecostsassociatedwithhidradenitissuppurativaatagermanuniversityhospital AT dagmarpresser economicanalysisofthecostsassociatedwithhidradenitissuppurativaatagermanuniversityhospital
_version_	1718374253742522368

Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.

Ejemplares similares